HMGB1 and acute myeloid leukemia: Third, HMGB1 modulates cell death modality switching: in AML, the deacetylase SIRT1 inhibits HMGB1 nuclear‐cytoplasmic shuttling, downregulates ACSL4, and blocks ferroptosis—conversely, SIRT1 deficiency promotes HMGB1 cytoplasmic accumulation, restores ACSL4‐mediated ferroptosis, and reverses cytarabine tolerance [121].